Efficacy of the mRNA SARS-CoV-2 vaccine in cancer patients during systemic therapy. A single-centre experience

J. Wnuk, Agnieszka Bobola, Łukasz Pietrzyński, I. Gisterek
{"title":"Efficacy of the mRNA SARS-CoV-2 vaccine in cancer patients during systemic therapy. A single-centre experience","authors":"J. Wnuk, Agnieszka Bobola, Łukasz Pietrzyński, I. Gisterek","doi":"10.5603/njo.a2023.0024","DOIUrl":null,"url":null,"abstract":"Introduction. A novel coronavirus, causing severe acute respiratory syndrome 2 (SARS-CoV-2) has spread globally since its emergence in December 2019. The mRNA SARS-CoV-2 vaccines have been proven to be an efficient and safe disease control means among adult patients without immunocompromising conditions. However, cancer patients were among the group of people that was initially excluded from the registration trials. Material and methods. 60 patients, enrolled to this study, had been voluntarily vaccinated either with the BNT162b2 or mRNA-1273 SARS-CoV-2 vaccine between March and June 2021 and have been undergoing systemic treatment in the Clinical Oncology Unit of the University Clinical Center of the Medical University of Silesia in Katowice, Poland. Patients received 2 injections of vaccine 21 days apart and were tested with Elecsys® Anti-SARS-CoV-2 immunoassay (Roche Diagnostics, France) for the presence of anti-S-protein antibodies in the patients’ serum. The serum samples were collected 2 to 8 weeks after receiving the second dose of vaccine. Results. The BNT162b2 vaccine was administered to 57 patients, while the mRNA-1273 vaccine – to 3 patients. Sero-conversion was achieved in 83.33% of patients. The median amount of anti-S-protein antibodies was 75,9 U/ml.There were no statistically significant differences in terms of age between the group with seroconversion and the group without seroconversion (Mann-Whitney U-test p = 0.762). There was no statistically significant correlation between neither the BMI (Spearman test, p = 0.079) norage (Spearman test, p = 0.762) and anti-S-protein antibody levels. Just as the diagnosis (primary tumor localization), clinical stage, type of modality (chemotherapy, chemoradiotherapy, immunotherapy) and the goal of treatment (radical, palliative) were not statistically significant in terms of anti-S-pro-tein antibody levels. Conclusions. Due to the high number of unresponsive or poorly responsive results, patients undergoing systemic therapy should be advised to maintain other measures of disease control such as distancing, usage of masks. Neverthe-less, implementing mRNA SARS-CoV-2 vaccinesinimmunocompromised patientsduring systemic therapyis reasoned, valuable and safe.","PeriodicalId":130080,"journal":{"name":"Nowotwory. Journal of Oncology","volume":"7 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nowotwory. Journal of Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5603/njo.a2023.0024","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction. A novel coronavirus, causing severe acute respiratory syndrome 2 (SARS-CoV-2) has spread globally since its emergence in December 2019. The mRNA SARS-CoV-2 vaccines have been proven to be an efficient and safe disease control means among adult patients without immunocompromising conditions. However, cancer patients were among the group of people that was initially excluded from the registration trials. Material and methods. 60 patients, enrolled to this study, had been voluntarily vaccinated either with the BNT162b2 or mRNA-1273 SARS-CoV-2 vaccine between March and June 2021 and have been undergoing systemic treatment in the Clinical Oncology Unit of the University Clinical Center of the Medical University of Silesia in Katowice, Poland. Patients received 2 injections of vaccine 21 days apart and were tested with Elecsys® Anti-SARS-CoV-2 immunoassay (Roche Diagnostics, France) for the presence of anti-S-protein antibodies in the patients’ serum. The serum samples were collected 2 to 8 weeks after receiving the second dose of vaccine. Results. The BNT162b2 vaccine was administered to 57 patients, while the mRNA-1273 vaccine – to 3 patients. Sero-conversion was achieved in 83.33% of patients. The median amount of anti-S-protein antibodies was 75,9 U/ml.There were no statistically significant differences in terms of age between the group with seroconversion and the group without seroconversion (Mann-Whitney U-test p = 0.762). There was no statistically significant correlation between neither the BMI (Spearman test, p = 0.079) norage (Spearman test, p = 0.762) and anti-S-protein antibody levels. Just as the diagnosis (primary tumor localization), clinical stage, type of modality (chemotherapy, chemoradiotherapy, immunotherapy) and the goal of treatment (radical, palliative) were not statistically significant in terms of anti-S-pro-tein antibody levels. Conclusions. Due to the high number of unresponsive or poorly responsive results, patients undergoing systemic therapy should be advised to maintain other measures of disease control such as distancing, usage of masks. Neverthe-less, implementing mRNA SARS-CoV-2 vaccinesinimmunocompromised patientsduring systemic therapyis reasoned, valuable and safe.
mRNA SARS-CoV-2疫苗在癌症患者全身治疗中的疗效单中心体验
介绍。自2019年12月出现以来,一种导致严重急性呼吸综合征2 (SARS-CoV-2)的新型冠状病毒已在全球传播。mRNA SARS-CoV-2疫苗已被证明是一种有效和安全的疾病控制手段,适用于没有免疫功能低下的成年患者。然而,癌症患者是最初被排除在注册试验之外的人群之一。材料和方法。参加这项研究的60名患者在2021年3月至6月期间自愿接种了BNT162b2或mRNA-1273 SARS-CoV-2疫苗,并在波兰卡托维兹西里西亚医科大学临床中心临床肿瘤科接受了全身治疗。患者间隔21天接受2次疫苗注射,并用Elecsys®Anti-SARS-CoV-2免疫分析法(法国罗氏诊断公司)检测患者血清中是否存在抗s蛋白抗体。接种第二剂疫苗后2 ~ 8周采集血清样本。结果。57例患者接种了BNT162b2疫苗,3例患者接种了mRNA-1273疫苗。83.33%的患者达到血清转化。抗s蛋白抗体中位数为75,9 U/ml。血清转换组与未血清转换组在年龄方面无统计学差异(Mann-Whitney u检验p = 0.762)。BMI (Spearman检验,p = 0.079)和年龄(Spearman检验,p = 0.762)与抗s蛋白抗体水平均无统计学意义。正如诊断(原发肿瘤定位)、临床分期、方式类型(化疗、放化疗、免疫治疗)和治疗目标(根治性、姑息性)在抗s -pro-tein抗体水平上无统计学意义。结论。由于大量无反应或反应差的结果,应建议接受全身治疗的患者保持其他疾病控制措施,如保持距离,使用口罩。尽管如此,免疫功能低下患者在全身治疗期间接种mRNA - cov -2疫苗是合理的、有价值的和安全的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信